Entasis Therapeutics Holdings Inc. (ETTX): Price and Financial Metrics


Entasis Therapeutics Holdings Inc. (ETTX): $3.11

0.20 (+6.87%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ETTX Stock Summary

  • Entasis Therapeutics Holdings Inc's stock had its IPO on September 26, 2018, making it an older stock than only 4.39% of US equities in our set.
  • The ratio of debt to operating expenses for Entasis Therapeutics Holdings Inc is higher than it is for about only 5.61% of US stocks.
  • Entasis Therapeutics Holdings Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -75.63%, greater than the shareholder yield of merely 6.2% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Entasis Therapeutics Holdings Inc, a group of peers worth examining would be CBIO, CDTX, LOGC, VCNX, and PULM.
  • ETTX's SEC filings can be seen here. And to visit Entasis Therapeutics Holdings Inc's official web site, go to www.entasistx.com.

ETTX Stock Price Chart Interactive Chart >

Price chart for ETTX

ETTX Price/Volume Stats

Current price $3.11 52-week high $3.74
Prev. close $2.91 52-week low $1.58
Day low $2.99 Volume 1,204,900
Day high $3.50 Avg. volume 318,454
50-day MA $2.57 Dividend yield N/A
200-day MA $2.52 Market Cap 147.13M

Entasis Therapeutics Holdings Inc. (ETTX) Company Bio


Entasis Therapeutics Inc. discovers and develops antibacterials to fight diseases caused by multidrug-resistant bacteria. It offers ETX2514, a broad-spectrum and potent inhibitor of class A, C, and D beta-lactamases that has activity against Acinetobacter baumannii, a gram-negative bacterium that causes severe infections, which are associated with high mortality; ETX0914, a novel oral antibiotic for the treatment of uncomplicated gonorrhea; and a drug discovery platform that focuses on developing novel antibacterials targeting serious gram-negative infections, such as pneumonia, infections of the blood, urinary tract infections, and infections following surgery. Entasis Therapeutics Inc. has strategic development collaboration with Zai Lab Limited. The company was founded in 2015 and is based in Waltham, Massachusetts. Entasis Therapeutics Inc. operates as a subsidiary of AstraZeneca PLC.


ETTX Latest News Stream


Event/Time News Detail
Loading, please wait...

ETTX Latest Social Stream


Loading social stream, please wait...

View Full ETTX Social Stream

Latest ETTX News From Around the Web

Below are the latest news stories about Entasis Therapeutics Holdings Inc that investors may wish to consider to help them evaluate ETTX as an investment opportunity.

Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature

Publication Details the Discovery and Preclinical Profile of ETX0462, a First-in-Class Candidate Against Multidrug-Resistant PathogensWALTHAM, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the publication of a profile of the company’s ETX0462 candidate in the prestigious scientific journal Nature (DOI: 10.1038/s41586-0

Yahoo | September 15, 2021

Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in the upcoming H.C. Wainwright 23rd Annual Global Investment Conference. Details of the Company’s participation are as follows: Conference: H.C. Wainwright 23rd Annual Global Investment ConferenceDates: September 13-15, 2021Format:

Yahoo | September 9, 2021

Will Entasis Therapeutics Holdings (NASDAQ:ETTX) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Yahoo | August 14, 2021

Entasis Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

-Management to Host Conference Call on August 12 at 8am ET-

Intrado Digital Media | August 11, 2021

Entasis Therapeutics to Host Expert Perspectives Webinar on Acinetobacter Infections

Virtual Event to be Held Tuesday, August 24 at 10am Eastern Time

Intrado Digital Media | August 10, 2021

Read More 'ETTX' Stories Here

ETTX Price Returns

1-mo 32.91%
3-mo 15.19%
6-mo 50.24%
1-year 8.74%
3-year N/A
5-year N/A
YTD 25.91%
2020 -50.30%
2019 22.11%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7669 seconds.